Transjugular Intrahepatic Portosystemic Shunt Reduction Techniques

Abstract

Transjugular intrahepatic portosystemic shunt (TIPS) creation treats complications of portal hypertension in appropriately selected patients by lowering the portal venous pressure. While this can be a lifesaving intervention, portal venous flow diversion is not without potential consequences. Overshunting can lead to hepatic decompensation and encephalopathy. TIPS reduction and TIPS occlusion are therapeutic options used to mitigate overshunting, with reduction being the initial alternative due to retained shunt patency and lower potential for venous thrombosis. Patient selection, techniques for TIPS reduction, and patient outcomes are reviewed in this article.

Keywords

occlusion - overt hepatic encephalopathy - portal hypertension - TIPS reduction - varices - interventional radiology

Publication History

Article published online:
04 May 2023

• References

• 1 Copelan A, Kapoor B, Sands M. Transjugular intrahepatic portosystemic shunt: indications, contraindications, and patient work-up. Semin Intervent Radiol 2014; 31 (03) 235-242
• 2 Suhocki PV, Lungren MP, Kapoor B, Kim CY. Transjugular intrahepatic portosystemic shunt complications: prevention and management. Semin Intervent Radiol 2015; 32 (02) 123-132
• 3 Van der Linden P, Le Moine O, Ghysels M, Ortinez M, Devière J. Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: effects on right ventricular function. Hepatology 1996; 23 (05) 982-987
• 4 Schindler P, Heinzow H, Trebicka J, Wildgruber M. Shunt-induced hepatic encephalopathy in TIPS: current approaches and clinical challenges. J Clin Med 2020; 9 (11) 3784
• 5 Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978; 23 (05) 398-406
• 6 Joseph AS, Sandhu B, Khalil A, Lopera J. Transjugular portosystemic shunt reductions: a retrospective single-center experience. J Vasc Interv Radiol 2019; 30 (06) 876-884
• 7 Wijdicks EF. Hepatic encephalopathy. N Engl J Med 2016; 375 (17) 1660-1670
• 8 de Wit K, Schaapman JJ, Nevens F. et al. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial). BMJ Open Gastroenterol 2020; 7 (01) e000531
• 9 Taylor AG, Kolli KP, Kerlan Jr RK. Techniques for transjugular intrahepatic portosystemic shunt reduction and occlusion. Tech Vasc Interv Radiol 2016; 19 (01) 74-81
• 10 Kochar N, Tripathi D, Ireland H, Redhead DN, Hayes PC. Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post-TIPSS refractory hepatic encephalopathy. Gut 2006; 55 (11) 1617-1623
• 11 Bilbao JI, Quiroga J, Herrero JI, Benito A. Transjugular intrahepatic portosystemic shunt (TIPS): current status and future possibilities. Cardiovasc Intervent Radiol 2002; 25 (04) 251-269
• 12 Casadaban LC, Parvinian A, Minocha J. et al. Clearing the confusion over hepatic encephalopathy after TIPS creation: incidence, prognostic factors, and clinical outcomes. Dig Dis Sci 2015; 60 (04) 1059-1066
• 13 Riggio O, Merlli M, Pedretti G. et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci 1996; 41 (03) 578-584
• 14 Gaba RC, Lakhoo J. What constitutes liver failure after transjugular intrahepatic portosystemic shunt creation? A proposed definition and grading system. Ann Hepatol 2016; 15 (02) 230-235
• 15 Paz-Fumagalli R, Crain MR, Mewissen MW, Varma RR. Fatal hemodynamic consequences of therapeutic closure of a transjugular intrahepatic portosystemic shunt. J Vasc Interv Radiol 1994; 5 (06) 831-834
• 16 Rose SE, Katz MD. Intentional occlusion of a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol 1995; 18 (02) 109-111
• 17 Haskal ZJ, Cope C, Soulen MC, Shlansky-Goldberg RD, Baum RA, Redd DC. Intentional reversible thrombosis of transjugular intrahepatic portosystemic shunts. Radiology 1995; 195 (02) 485-488
• 18 Kerlan Jr RK, LaBerge JM, Baker EL. et al. Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 1995; 6 (06) 917-921
• 19 Freedman AM, Sanyal AJ, Tisnado J. et al. Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review. Radiographics 1993; 13 (06) 1185-1210
• 20 Jalan R, Hayes PC. Risk of intentional reversible thrombosis of transjugular intrahepatic portosystemic shunt. Radiology 1995; 197 (03) 587
• 21 Gerbes AL, Waggershauser T, Holl J, Gülberg V, Fischer G, Reiser M. Experiences with novel techniques for reduction of stent flow in transjugular intrahepatic portosystemic shunts. Z Gastroenterol 1998; 36 (05) 373-377
• 22 Haskal ZJ, Middlebrook MR. Creation of a stenotic stent to reduce flow through a transjugular intrahepatic portosystemic shunt. J Vasc Interv Radiol 1994; 5 (06) 827-829 , discussion 829–830
• 23 Patel RK, Chandel K, Tripathy TP, Mukund A. Complications of transjugular intrahepatic portosystemic shunt (TIPS) in the era of the stent graft - What the interventionists need to know?. Eur J Radiol 2021; 144: 109986
• 24 Blue RC, Lo GC, Kim E. et al. Transjugular intrahepatic portosystemic shunt flow reduction with adjustable polytetrafluoroethylene-covered balloon-expandable stents using the “sheath control” technique. Cardiovasc Intervent Radiol 2016; 39 (06) 935-939
• 25 Sarwar A, Esparaz AM, Chakrala N. et al. Efficacy of TIPS reduction for refractory hepatic encephalopathy, right heart failure, and liver dysfunction. AJR Am J Roentgenol 2021; 216 (05) 1267-1272
• 26 Fanelli F, Salvatori FM, Rabuffi P. et al. Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft. AJR Am J Roentgenol 2009; 193 (06) 1696-1702